Afatinib versus osimertinib for non–small cell lung cancer with uncommon epidermal growth factor receptor mutations: Real-world outcomes (HOT-Next001/HOT2501).
Yutaro Nagano, Hiroshi Yokouchi, Ryota Saito, Osamu Honjo et autres
jp (code pays fourni par la source)
0 citations
Journal of Clinical Oncology